rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
MDR1-C3435T genotype might emerge as a potential biomarker to predict the risk of cytogenetic relapse in patients with CML.
|
28367681 |
2017 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Three single-nucleotide polymorphisms (C1236T, G2677T/A, C3435T) and/or mRNA expression changes of ABCB1 gene were demonstrated to be associated with inter-individual variability of imatinib response in CML patients.
|
28836054 |
2017 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We therefore studied three polymorphisms (C1236T, G2677T and C3435T) in the human multidrug-resistance gene (MDR1) in 86 patients with chronic myeloid leukaemia treated with imatinib.
|
27294449 |
2016 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Genetic polymorphisms in CYP3A5*3 and ABCB1 C3435T are associated with TPC in CML patients in this population.
|
27426203 |
2016 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis suggests that c.1236C>T, c.2677G>T/A and c.3435C>T can be served as predictive markers for the therapeutical use of imatinib in CML patients.
|
25245580 |
2015 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
However, no significant association was found for the MDR1 G2677T or C3435T polymorphisms in an Asian CML population as well as a Caucasian CML population.
|
24798723 |
2014 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Three ABCB1 SNPs (C1236T, G2677T, and C3435T) were genotyped in 100 Egyptian patients with CML undergoing IM therapy using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.
|
25301112 |
2014 |
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We investigated the MDR1 T1236C, G 2677T/A, and C3435T polymorphism in 52 patients with chronic myeloid leukemia treated with imatinib.
|
20204543 |
2011 |
rs2032582
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Three single-nucleotide polymorphisms (C1236T, G2677T/A, C3435T) and/or mRNA expression changes of ABCB1 gene were demonstrated to be associated with inter-individual variability of imatinib response in CML patients.
|
28836054 |
2017 |
rs2032582
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We therefore studied three polymorphisms (C1236T, G2677T and C3435T) in the human multidrug-resistance gene (MDR1) in 86 patients with chronic myeloid leukaemia treated with imatinib.
|
27294449 |
2016 |
rs2032582
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion, based on our meta-analysis, the MDR1 polymorphisms, rs1045642, rs1128503, and rs2032582, are not directly correlated with the curative effect of IM treatment of CML patients.
|
26634458 |
2015 |
rs2032582
|
|
|
0.040 |
GeneticVariation |
BEFREE |
To investigate the genotype frequencies of single nucleotide polymorphisms (SNPs) G2677T in CML patients undergoing imatinib treatment to determine whether different genotype pattern of these SNPs have any influence in mediating response to imatinib.
|
23683876 |
2014 |
rs1128503
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, determination of C1236T MDR1 genotype may help to predict response to imatinib therapy in patients with chronic myeloid leukaemia.
|
27294449 |
2016 |
rs1128503
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The synonymous MDR1 C1236T polymorphism might be a risk factor for nonoptimal clinical response to imatinib in Asian CML patients.
|
24798723 |
2014 |